A 57-year-old woman with BRAF-positive metastatic melanoma presented to the dermatology clinic for evaluation of rapidly growing nodules on her face and warty growths over her trunk and extremities 3 months after initiating vemurafenib therapy. In 2007, this patient was diagnosed with an amelanotic melanoma on her right posterior scalp (Breslow depth, 6.9 mm) with a single neck lymph node that was positive for metastatic disease. She declined systemic treatment and radiation at that time and again after a negative positron emission tomography scan in 2009. She was lost to follow-up from dermatology and oncology clinics until 2012, when she presented with confusion, memory loss, and word-finding difficulties. At that time she was found to have a left frontal mass, numerous pulmonary nodules, and mediastinal lymphadenopathy. She underwent resection of the brain mass and whole-brain irradiation. She then began receiving treatment with vemurafenib in May 2012. In addition to her history of melanoma, this patient had a history of several nonmelanoma skin cancers.
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On clinical examination, our patient's skin was diffusely xerotic with prominent hair follicles resembling keratosis pilaris. There was a 1.8 ϫ 1.3-cm erythematous tender nodule with a central crust on the right central forehead and a similar-appearing nodule on the chin that measured 1.2 ϫ 1.2 cm. Figs 1A and 1B are photographs of these lesions from the patient's initial dermatology evaluation. There were also several verrucous-appearing hyperkeratotic papules on the chest, back, and abdomen. Skin biopsies of the facial nodules revealed well-differentiated, invasive squamous cell carcinomas (SCCs), one with keratoacanthomatous features. A biopsy of two of the verrucous papules, one on the abdomen and another on the right leg, revealed well-differentiated, invasive SCCs with verrucous features.
Cutaneous adverse events are common in patients treated with vemurafenib, likely because of changes in cell signaling pathways that occur when BRAF is inhibited. During phase I, II, and III clinical trials, rash was reported in 36% to 68% of patients, photosensitivity in 30% to 52% of patients, and cutaneous SCCs in 12% to 26% of patients. 
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including keratosis pilaris-like eruptions, changes in nevi, the development of numerous verrucae, and well-differentiated invasive SCCs and keratoacanthomas (KAs). [1] [2] [3] [4] [5] [6] [7] KAs are generally considered to be a variant of SCCs because they have the ability to metastasize, and they are treated as such by dermatologists. In one case series of 14 patients receiving BRAF inhibitors (vemurafenib or dabrafenib), 57% of patients developed well-differentiated SCCs between 1 and 56 weeks after initiation of BRAF inhibitor treatment. 4 In another case report of 15 patients who received vemurafenib, 26.7% developed at least one SCC and 13.5% developed multiple SCCs. 6 The rapidity with which KAs and SCCs develop in patients taking BRAF inhibitors presents a treatment challenge. In the cases discussed in the literature, KAs and SCCs have been successfully managed with Mohs micrographic surgery, excision, curettage, and electrodessication and cryotherapy. 4, 6, 7 There is a case report of successful management of eruptive KAs with photodynamic therapy 8 and a report of a systemic retinoid, acitretin, that reduced the number of new nonmelanoma skin cancers in a patient taking vemurafenib. 9 In the case of our patient, the standard of care for the SCCs on her forehead and chin was Mohs micrographic surgery, given that tissue conservation was a priority at both locations. Excision with 0.5-cm margins was the standard of care for the SCCs on the trunk and extremities, given that neither was larger than 2 cm in diameter. Because of the size and location of the SCCs on the face, it was anticipated that the surgical procedures required to completely excise the neoplasms and reconstruct the face with optimal cosmetic results would be quite extensive, with significant recovery time involved. This patient had a poor long-term prognosis with extensive metastatic disease; therefore, nonsurgical treatment options were considered.
Intralesional agents that have been used to treat cutaneous SCCs and KAs include fluorouracil, methotrexate, interferon, and bleomycin. Fluorouracil typically requires several weekly injections until adequate response is observed; it has been successful in treating KAs and invasive SCCs, with reported cure rates greater than 90%. 10 Because of the pain during infiltration, fluorouracil injections require local anesthesia before injection. Methotrexate injections have also been used to treat KAs and SCCs. The benefits of methotrexate over fluorouracil include less frequent injections (every 3 to 4 weeks), decreased cost (less than $2 for a 2-mL vial of 25 mg/mL methotrexate), and no need for local anesthesia.
10,11 In a case series of 38 KAs treated with methotrexate, there was a complete response rate of 92%. 11 Two cases have been reported of pancytopenia after intralesional methotrexate injection; both occurred in patients with renal failure on hemodialysis, so it is recommended that CBC be obtained at baseline and 1 week after injection in such patients. 11 Recently, there have been several reports of successful use of neoadjuvant intralesional methotrexate for KAs and SCCs before planned surgery to achieve better cosmetic outcomes.
12,13 There have also been case reports and case series of interferon-␣-2a, interferon-␣-2b, and bleomycin to treat KAs with adequate lesion regression and acceptable cosmetic results.
10 Similar to fluorouracil, bleomycin injections require local anesthesia before infiltration.
For our patient, the decision was made to treat with intralesional methotrexate injections. A considerable amount of methotrexate volume exudes from the surface of the tumor at the time of infiltration. Consequently, the exact volume that remains infiltrated in the tumor can only be estimated; it is assumed that approximately half of the injected methotrexate remains in the tumor after each treatment. The patient received up to 50 mg of methotrexate (25 mg/mL) intralesionally at each visit, initially into the two SCCs on her face and then into four papules and nodules that were clinically consistent with SCC on the thigh, back, and calf, as they arose. She underwent four methotrexate injections on the chin and three injections on the forehead, each spaced 3 to 4 weeks apart. The amount of methotrexate that was assumed to be infiltrated (50% of the amount injected) for each injection on the chin was 12.5 mg (1.0 mL injected), 12.5 mg (1.0 mL injected), 6.3 mg (0.5 mL injected), and 5.0 mg (0.4 mL injected), respectively. The amount for each injection on the forehead was 12.5 mg (1.0 mL injected), 9.4 mg (0.75 mL injected), and 1.9 mg (0.15 mL injected), respectively.
There was modest improvement in the appearance and tenderness of the facial SCCs after the first round of injections, and marked improvement at both sites after the second round. After three injections, the right forehead lesion measured 6 mm and the chin lesion measured 8 mm; both were significantly improved, as can be seen in Figs 1C and 1D, which were taken immediately before the fourth injection. The patient's CBC remained stable throughout treatment with methotrexate. At each of her follow-up visits, small papules consistent with actinic keratoses and small SCCs (Ͻ 5 mm) were treated with cryotherapy. She reported tolerable pain with injections and some tenderness following injections but otherwise no adverse effects. Unfortunately, vemurafenib therapy was discontinued shortly after her fourth methotrexate injection because of melanoma disease progression. It is anticipated that the rate of development of KAs and SCCs should sharply decline and that her current lesions will continue to improve after discontinuation of vemurafenib.
Discussion
BRAF inhibitors such as vemurafenib represent an excellent treatment option for patients with metastatic melanoma. As more patients are treated with BRAF inhibitors, the cost and morbidity associated with treating the cutaneous adverse effects will become more important. It will be important to reconsider typical management guidelines for the treatment of nonmelanoma skin cancers and tailor treatment to make it appropriate for each patient. Although this patient was given the option of Mohs micrographic surgery for her large facial SCCs, she deemed it more prudent to attempt to clear the tumors with injections, considering her preexisting poor prognosis and the considerable discomfort and recovery associated with Mohs and random pattern flap reconstruction. Our patient's KAs and SCCs were treated in a cost-effective manner, she had an acceptable cosmetic outcome, and her dermatologic care did not require extra visits to our institution for treatment because her dermatology and oncology appointments were coordinated.
